Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Passage Bio Inc PASG

Healthcare Biotechnology
Passage Bio, Inc. is a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases. Its clinical product candidate, PBFT02, seeks to elevate progranulin levels to restore lysosomal function and slow disease progression across a variety of neurodegenerative diseases. PBFT02 utilizes an adeno-associated virus capsid to deliver a functional... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:PASG)

Passage Bio Presents Preclinical and Interim Clinical Data for PBFT02 in FTD-GRN at the European Society of Gene & Cell Therapy (ESGCT) 31st Annual Conference

GlobeNewswire 12 days ago

Passage Bio to Present at Chardan's 8th Annual Genetic Medicines Conference

GlobeNewswire September 23, 2024

Passage Bio to Present Positive Interim Data from Cohort 1 Patients with FTD-GRN in upliFT-D Study at 14th International Conference on Frontotemporal Dementias (ISFTD2024)

GlobeNewswire September 16, 2024

Passage Bio Welcomes Tom Kassberg to Board of Directors

GlobeNewswire September 10, 2024

Passage Bio to Present at H.C. Wainwright 26th Annual Global Investment Conference

GlobeNewswire August 30, 2024

Passage Bio Reports Second Quarter 2024 Financial Results and Provides Recent Business Highlights

GlobeNewswire August 8, 2024

Passage Bio to Participate in Upcoming Investor Conferences

GlobeNewswire August 6, 2024

Passage Bio Out-licenses Three Pediatric Gene Therapy Programs to GEMMA Biotherapeutics and Enters New Research Collaboration

GlobeNewswire August 1, 2024

Passage Bio Announces Positive Feedback from FDA on Expansion of upliFT-D Trial of PBFT02 to Include FTD-C9orf72 Patients

GlobeNewswire July 16, 2024
View More News ››

Opinion & Analysis (NDAQ:PASG)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:PASG)

Passage Bio Announces Recipient of Third Annual Tachi Yamada

JUST IN: $PASG Passage Bio Announces Recipient of Third Annual Tachi Yamada Scholarship AwardPHILADELPHIA, May 21, 2024 (GLOBE NEWSWIRE)...
whytestocks - May 21, 2024
View more Bullboard ››

Tenet Fintech Group Inc.

Tenet Fintech Group Inc.

Tenet Fintech Group Inc. is the parent company of a group of innovative financial technology (Fintech) and artificial ...
View More »